A+ | A | A- | Skip to main content |

800 years stamp

Sensex

Nifty

USDINR

GBPINR

EURINR

BSE
NSE

Friday, 10 April 2026 12:00 AM EOD	Asian-Paints2359.40	Hind-Unilever2155.60	ITC304.20	Trent3918.70	Larsen-and-Toubro3959.90	M-and-M3261.80	Reliance-Industries1350.15	Tata-Steel206.60	Titan-Company4502.15	SBI1066.70	Bharat-Electron442.30	Kotak-Mah-Bank374.75	Infosys1292.35	Bajaj-Finance924.40	Sun-PharmaInds1654.70	HDFC-Bank810.40	TCS2524.35	ICICI-Bank1322.00	Power-Grid-Corpn302.60	Maruti-Suzuki13710.95	Axis-Bank1351.45	HCL-Technologies1450.90	NTPC380.30	Bharti-Airtel1870.00	Tech-Mahindra1440.40	Adani-Ports1475.10	UltraTech-Cem11589.90	Bajaj-Finserv1808.60	Interglobe-Aviat4555.80	Eternal240.25
15 mins delay SENSEX 77,550.25 [918.60]	90.05 3.97%	21.90 1.03%	1.20 0.40%	69.20 1.80%	62.70 1.61%	94.50 2.98%	20.75 1.56%	1.35 0.66%	65.25 1.47%	25.80 2.48%	2.50 0.57%	2.80 0.75%	-39.15 -2.94%	20.80 2.30%	-62.65 -3.65%	13.15 1.65%	-63.40 -2.45%	41.25 3.22%	4.45 1.49%	121.10 0.89%	32.85 2.49%	-14.30 -0.98%	1.85 0.49%	11.20 0.60%	-21.05 -1.44%	27.80 1.92%	147.85 1.29%	41.45 2.35%	107.45 2.42%	2.35 0.99%

Hot Pursuit

Scrips, which has significant changes during the market hours.

Panacea Biotec bags Rs 20.79 crore LoA from Central Medical Services Society

11-Apr-26 17:11Hrs IST

As per the terms, the company will supply Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents (Td Vaccine) in multiple tranches. The supplies are scheduled to commence from September/October 2026 and continue till November/December 2028.

The company clarified that the order has been awarded by a domestic entity and is in the nature of vaccine supply. It further stated that neither its promoters nor promoter group entities have any interest in the awarding authority, and the transaction does not fall under related-party transactions.

Panacea Biotec is a research-based biotechnology company engaged in the business of research, development, manufacture, and marketing vaccines in India and international markets.

The company reported a consolidated net loss of Rs 7.36 crore in Q3 FY26 as against a net profit of Rs 9.65 crore in Q3 FY25. Revenue from operations declined 8.4% year on year to Rs 99.31 crore in Q3 FY26.

Shares of Panacea Biotec rose 1.23% to end at Rs 326 on 10 April 2026.

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."

A Muthoot M George Enterprise